Path Fertility is a reproductive health brand focused on helping patients and fertility providers better understand male fertility potential. Its flagship product, SpermQT, is a functional sperm test designed to assess abilities that standard semen analysis does not measure, including sperm’s capacity to find, bind to, and penetrate an egg and support fertilization. The company says the test is six times more predictive of fertility potential than standard semen analysis, and presents it as an additional source of information for decisions such as whether to continue intrauterine insemination or consider in vitro fertilization.

SpermQT is intended for men and couples navigating fertility care. Samples can be collected at a doctor’s office or at home using a test kit, then sent to a laboratory for analysis; results are delivered within two weeks. Path Fertility provides information and resources for both prospective parents and clinicians, including scientific research and guidance on using results in treatment planning.